A-3 Price List_Adquey-Atopic-Topical Agents.xlsx

XLSX spreadsheet 57 KB Posted

Attached to
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Solicitation number
HT9402-26-Q-9404
Issued by

About this file

This is a price list template for the Department of War Pharmacy and Therapeutics (P&T) Committee's November 2026 Uniform Formulary review meeting for atopic topical agents. The document serves as a submission template for pharmaceutical manufacturers bidding on Blanket Purchase Agreements (BPA) and Additional Discount Programs (ADP) for inclusion in the TRICARE pharmacy benefit program. Quotes are due by October 26, 2026, and the P&T Committee will meet November 4-5, 2026, to make formulary placement decisions that determine cost-sharing tiers and reimbursement methods for TRICARE beneficiaries.

The template includes multiple appendices for ten newly approved drug candidates, each requiring manufacturers to submit pricing information across different formulary scenarios: Uniform Formulary (UF) with before-step and after-step therapy options, and tiered pricing for the Additional Discount Program (Tier 2 and Tier 3 status). For the BPA sections, manufacturers must provide price per unit and price per package size for Military Treatment Facility and Mail Order channels. For the ADP sections, manufacturers must specify non-FAMP pricing, Federal Ceiling Price (FCP) information, and additional refund percentages for TRICARE Retail, or alternatively, Wholesale Acquisition Cost (WAC) discount percentages. The document emphasizes that manufacturers must submit fully executed signature pages and a Quote Review Checklist alongside pricing data. Prior authorization may apply, and the P&T Committee may designate agents for preferential status, step therapy requirements with grandfathering provisions for current patients, or complete exclusion from the pharmacy benefit program based on relative clinical and cost effectiveness.

View the file

Other files

Show all 15

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service. The P&T Committee may consider approving specialist bypass for the step-preferred (before-step) agent.

*Note: Step Therapy may be applicable to agents that share the same FDA-approved indication(s).

Agents with RFQ not submitted or selected may be designated non-step preferred (after-step).

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#5DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#10DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
Scenario 1: One agent UF and before the step.
Scenario 1271ATTOG1UFBS1Uniform Formulary
Before-Step Therapy1NO QUOTE
271ATTOG1UFAS1MUniform Formulary
After-Step Therapy1 or moreNO QUOTE
271ATTOG1NFAS1MNon-Formulary
After-Step Therapy1 or moreNO QUOTE
Scenario 2: One or more agents UF.
Scenario 2271ATTOG1UF1MUniform Formulary1 or moreNO QUOTE
271ATTOG1NF1MNon-Formulary1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

ADP (non-FAMP Discount)

UF ADP Appendix for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service. The P&T Committee may consider approving specialist bypass for the step-preferred (before-step) agent.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

ADP (WAC Discount)

UF ADP Appendix for the November 2026 DoW P&T Meeting
DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
Formulary Notes
Class Note(s): This agent will be reviewed at the upcoming quarterly P&T Committee meeting according to 32 CFR 199.21(g)(5). Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the P&T Committee may identify candidates to recommend complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: Grandfathering: a prior authorization process that allows current patients to remain on current therapy and requires new patients to complete an adequate trial of the step-preferred (before-step) agent before a non-step-preferred (after-step) agent is provided to the patient at any MTF, Retail, or Mail point of service. The P&T Committee may consider approving specialist bypass for the step-preferred (before-step) agent.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
0
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DoW Uniform Formulary Class:ATOPYP&T Committee Meeting:November 4-5, 2026
DoW Uniform Formulary Subclass:TOPICAL AGENTSQuotes due:October 26, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
Scenario 1: One agent T2 and before the step.
Scenario 1271ATTOG1T2BS1Tier 2
Before-Step Therapy1
271ATTOG1T2AS1MTier 2
After-Step Therapy1 or more
271ATTOG1T3AS1MTier 3
After-Step Therapy1 or more
Scenario 2: One or more agents T2.
Scenario 2271ATTOG1T21MTier 21 or more
271ATTOG1T31MTier 31 or more
If cell highlights red, please confirm intent not to submit a quote

&"-,Italic"Use or disclosure of data contained on this sheet is subject to the restriction on the title page of this quote.

File details come from the government source that posted it. Updated .